Savolitinib is a targeted therapy agent indicated for specific malignancies. Common side effects include nausea, edema, abnormal liver and renal function, and changes in hematological parameters. Dosage adjustments should be made based on individual conditions, with close monitoring throughout treatment.
I. Common Side Effects
Gastrointestinal Reactions
Approximately 30%-50% of patients may experience nausea, vomiting, diarrhea or decreased appetite. These symptoms can be alleviated through dietary adjustments, divided-dose administration or the use of anti-emetic drugs.
Edema
Facial or limb edema is relatively common and usually mild. In severe cases, cardiac or renal function should be evaluated, and dosage adjustment may be required if necessary.
Abnormal Liver and Renal Function
Savolitinib may cause elevated transaminase levels and changes in serum creatinine concentrations. Regular monitoring of these indicators is essential. Treatment should be suspended or dosage adjusted if abnormalities occur.
II. Hematological Effects
Anemia or Thrombocytopenia
Some patients may develop decreased hemoglobin levels or thrombocytopenia. Regular blood routine tests are recommended. In severe cases, blood transfusion or treatment suspension may be indicated.
Leukopenia
This condition may increase the risk of infection. Patients should monitor their body temperature closely and watch for signs of infection. Granulocyte-colony stimulating factors (G-CSF) may be administered when necessary.
III. Other Potential Risks
Dermatological Reactions
Manifestations such as skin rash and pruritus can be managed with antihistamines if mild. Treatment discontinuation is required for severe reactions.
Cardiovascular Disorders
A small number of patients may develop hypertension or QT interval prolongation. Regular monitoring of blood pressure and electrocardiography (ECG) is recommended.
Fatigue
Fatigue has been reported in approximately 20% of patients. A balanced schedule of rest and physical activity is advised.
IV. Precautions
Individual Variability
The incidence and severity of side effects vary among individuals, which are associated with underlying diseases, concomitant medications, and other factors.
Monitoring and Intervention
During treatment, regular monitoring of liver and renal function, blood routine, and ECG is required. Immediate medical attention should be sought if severe edema, dyspnea, jaundice or persistent high fever occurs.
Drug Interactions
Concurrent use with potent CYP3A4 inhibitors or inducers should be avoided, as it may affect drug efficacy or increase toxicity.
Savolitinib is a prescription-only medication. Its use must strictly follow the doctor’s instructions, and dosage adjustment or treatment discontinuation shall not be conducted without authorization. Patients should maintain close communication with physicians during treatment and promptly report any abnormal symptoms.
